Novo Nordisk and Viatris have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy ...

Novo Nordisk says Massachusetts plays a key role in its bid to expand beyond its historic focus as a diabetes and obesity ...

Novo Nordisk is investing $158 million to revamp a plant in Brazil responsible for a quarter of the Danish company’s global ...

Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter ...

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

The general mood among these heavyweight investors is divided, with 45% leaning bullish and 50% bearish. Among these notable ...

Novo Nordisk plans to invest approximately $158 million into revamping its Montes Claros manufacturing facility in Minas Gerais, Brazil, Bloomberg reported Oct. 5.

Natco Pharma shares rise 3% as partner Mylan settles U.S. patent litigation with Novo Nordisk for generic Ozempic.

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

In terms of liquidity and interest, the mean open interest for Novo Nordisk options trades today is 703.94 with a total ...